en
Scientific article
Open access
French

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo

Published inClinical infectious diseases, vol. 56, no. 2, p. 195-203
Publication date2013
Abstract

Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).

Citation (ISO format)
ALIROL, Emilie et al. Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo. In: Clinical infectious diseases, 2013, vol. 56, n° 2, p. 195–203. doi: 10.1093/cid/cis886
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1058-4838
582views
349downloads

Technical informations

Creation12/06/2013 1:10:00 PM
First validation12/06/2013 1:10:00 PM
Update time03/14/2023 8:55:28 PM
Status update03/14/2023 8:55:28 PM
Last indexation01/16/2024 2:05:50 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack